A phase 2, twelve month, randomized, controlled trial of combined treatment for exudative age related macular degeneration with variable dosing Ranibizumab (Lucentis) and Sub-Tenon Triamcinolone (Kenacort-A 40).

Age-related macular degeneration (AMD) is a common eye condition that causes blurry vision or vision loss in the center of your field of view. The "wet" or exudative form of AMD involves abnormal blood vessels growing under the retina and leaking fluid. This study is testing a treatment plan that combines ranibizumab (Lucentis — an injection given into the eye) with regular triamcinolone (a steroid given around the eye) to find out if this combination can maintain or improve vision while reducing the number of injections needed compared to current standard treatments. You may be eligible if: - You are 50 years or older - You have active wet AMD affecting the central area of the retina (the fovea) - The thickness of your retina measured by OCT scan is greater than 300 microns - Your best-corrected vision is between 20/40 and 20/400 - Your kidney function is adequate You may NOT be eligible if: - You have had previous laser treatment directly under the central retina in the study eye - There is scarring or atrophy under the center of the retina - You have had vitrectomy (eye surgery) in the study eye - You are pregnant or of childbearing age and not using contraception - You have uncontrolled glaucoma - You have a known allergy to ranibizumab or triamcinolone - You are known to have a strong response to steroids - You are on high-dose oral steroids (5 mg prednisolone or more daily) Talk to your doctor about whether this trial might be right for you.